Clinical trials

PET Imaging

We completed human 18F PET nuclear imaging clinical study with pHLIP® peptide at the Memorial Sloan Kettering Cancer Center. The identifier is NCT04054986,

Fluorescence-Guided Surgery

Fluorescence-guided surgical clinical trial with pHLIP® ICG imaging agent will be initiated at the Memorial Sloan Kettering Cancer Center in 2021.


Cybrexa Therapeutics (pHLIP, Inc sublicensee) announced that the first patient has been dosed in a Phase 1/2 clinical trial evaluating CBX-12 (alphalex™-exatecan, where alphalex™ consists of a pHLIP® peptide and linker), the company’s lead therapeutic candidate. The identifier is NCT04902872,